Scandinavian Real Heart AB (Publ) (HEART.ST)
SEK 12.54
(-2.79%)
SEK 12.54
(-2.79%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -67.97 Million SEK | -385.97% |
| 2022 | -13.98 Million SEK | -33.43% |
| 2021 | -10.48 Million SEK | -18.85% |
| 2020 | -8.82 Million SEK | -20.99% |
| 2019 | -7.29 Million SEK | 17.7% |
| 2018 | -8.85 Million SEK | 35.55% |
| 2017 | -13.74 Million SEK | -253.86% |
| 2016 | -3.88 Million SEK | -153.78% |
| 2015 | -1.53 Million SEK | 9.45% |
| 2014 | -1.69 Million SEK | -556.32% |
| 2013 | -257.53 Thousand SEK | -1812.02% |
| 2012 | -13.46 Thousand SEK | 84.45% |
| 2011 | -86.59 Thousand SEK | 25.85% |
| 2010 | -116.79 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | - SEK | 100.0% |
| 2024 Q1 | -7.78 Million SEK | 85.28% |
| 2023 FY | -67.97 Million SEK | -385.97% |
| 2023 Q2 | -2.96 Million SEK | 27.72% |
| 2023 Q1 | -4.1 Million SEK | -183.14% |
| 2023 Q3 | -8.01 Million SEK | -170.49% |
| 2023 Q4 | -52.89 Million SEK | -559.81% |
| 2022 Q1 | -2.7 Million SEK | 46.65% |
| 2022 FY | -13.98 Million SEK | -33.43% |
| 2022 Q4 | 4.93 Million SEK | 64.47% |
| 2022 Q3 | 2.99 Million SEK | 193.45% |
| 2022 Q2 | -3.2 Million SEK | -18.76% |
| 2021 Q2 | -2.22 Million SEK | -25.34% |
| 2021 FY | -10.48 Million SEK | -18.85% |
| 2021 Q1 | -1.77 Million SEK | 19.12% |
| 2021 Q4 | -5.06 Million SEK | -259.16% |
| 2021 Q3 | -1.41 Million SEK | 36.76% |
| 2020 Q2 | -1.79 Million SEK | 23.42% |
| 2020 Q1 | -2.33 Million SEK | -132.28% |
| 2020 Q3 | -2.49 Million SEK | -39.12% |
| 2020 Q4 | -2.19 Million SEK | 11.7% |
| 2020 FY | -8.82 Million SEK | -20.99% |
| 2019 Q2 | -2.33 Million SEK | -43.74% |
| 2019 Q4 | 7.24 Million SEK | 648.93% |
| 2019 Q3 | -1.31 Million SEK | 43.49% |
| 2019 FY | -7.29 Million SEK | 17.7% |
| 2019 Q1 | -1.62 Million SEK | 65.53% |
| 2018 FY | -8.85 Million SEK | 35.55% |
| 2018 Q4 | -4.71 Million SEK | -158.03% |
| 2018 Q3 | -1.82 Million SEK | -38.41% |
| 2018 Q2 | -1.31 Million SEK | 19.47% |
| 2018 Q1 | -1.63 Million SEK | 84.8% |
| 2017 Q3 | -1.48 Million SEK | -55.55% |
| 2017 FY | -13.74 Million SEK | -253.86% |
| 2017 Q1 | -564.17 Thousand SEK | 37.01% |
| 2017 Q2 | -951.66 Thousand SEK | -68.68% |
| 2017 Q4 | -10.77 Million SEK | -628.14% |
| 2016 Q1 | -807.7 Thousand SEK | -31.76% |
| 2016 FY | -3.88 Million SEK | -153.78% |
| 2016 Q4 | -895.67 Thousand SEK | -13.43% |
| 2016 Q3 | -789.61 Thousand SEK | 45.54% |
| 2016 Q2 | -1.45 Million SEK | -79.52% |
| 2015 Q1 | -451.5 Thousand SEK | 56.43% |
| 2015 FY | -1.53 Million SEK | 9.45% |
| 2015 Q4 | -613.01 Thousand SEK | -174.14% |
| 2015 Q3 | -223.61 Thousand SEK | 7.74% |
| 2015 Q2 | -242.37 Thousand SEK | 46.32% |
| 2014 FY | -1.69 Million SEK | -556.32% |
| 2014 Q3 | -343.57 Thousand SEK | -165.92% |
| 2014 Q2 | -129.2 Thousand SEK | 28.71% |
| 2014 Q4 | -1.03 Million SEK | -201.59% |
| 2014 Q1 | -181.23 Thousand SEK | 0.0% |
| 2013 FY | -257.53 Thousand SEK | -1812.02% |
| 2012 FY | -13.46 Thousand SEK | 84.45% |
| 2011 FY | -86.59 Thousand SEK | 25.85% |
| 2010 FY | -116.79 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 12.669% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 165.679% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 165.679% |
| Arcoma AB | 2.56 Million SEK | 2751.22% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 50.877% |
| BICO Group AB (publ) | -835.7 Million SEK | 91.866% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 372.16% |
| CellaVision AB (publ) | 130.3 Million SEK | 152.166% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 14.807% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | -132.905% |
| C-Rad AB (publ) | 35.52 Million SEK | 291.329% |
| Duearity AB (publ) | -26.19 Million SEK | -159.554% |
| Dignitana AB (publ) | -17.36 Million SEK | -291.507% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 28.294% |
| Getinge AB (publ) | 2.41 Billion SEK | 102.818% |
| Iconovo AB (publ) | -45.89 Million SEK | -48.119% |
| Integrum AB (publ) | 4.03 Million SEK | 1785.745% |
| Luxbright AB (publ) | -25.37 Million SEK | -167.889% |
| Mentice AB (publ) | -2.81 Million SEK | -2313.109% |
| OssDsign AB (publ) | -130.49 Million SEK | 47.907% |
| Paxman AB (publ) | 8.33 Million SEK | 916.054% |
| Promimic AB (publ) | -9.22 Million SEK | -637.121% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 57.503% |
| SciBase Holding AB (publ) | -55.58 Million SEK | -22.294% |
| ScandiDos AB (publ) | -14.64 Million SEK | -364.104% |
| Sectra AB (publ) | 428.38 Million SEK | 115.868% |
| Sedana Medical AB (publ) | -59.61 Million SEK | -14.033% |
| Senzime AB (publ) | -134.14 Million SEK | 49.327% |
| SpectraCure AB (publ) | -20.44 Million SEK | -232.554% |
| Stille AB | 26.64 Million SEK | 355.113% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 98.235% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 174.033% |